Topics

Hansoh Forms $1.5 Billion Partnership with Atomwise, an AI Drug Discovery Company

04:19 EDT 13 Sep 2019 | ChinaBio Today

Hansoh Pharma of China announced a blockbuster $1.5 billion small molecule drug discovery collaboration with Atomwise, a San Francisco AI company. Atomwise will use its structure-based drug discovery programs to identify drug candidates for up to eleven target proteins in multiple therapeutic areas. Hansoh will make payments to Atomwise and hold global rights to any products, though Atomwise will receive royalties and participate in any sales or licensings. Hansoh, which completed a $1 billion IPO on the Hong Kong Exchange in June, is headquartered in Lianyuangang, Jiangsu Province. More details....

Share this with colleagues:

Original Article: Hansoh Forms $1.5 Billion Partnership with Atomwise, an AI Drug Discovery Company

NEXT ARTICLE

More From BioPortfolio on "Hansoh Forms $1.5 Billion Partnership with Atomwise, an AI Drug Discovery Company"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...